Could the depression of obese patients suffering from chronic hepatitis C be temporarily improved?

Journal of Viral Hepatitis

Volumn 15, Issue 9, 2008, Pages 646-650

  Tarantino, G ^a   Basile, V ^a   Conca, P ^a   Ariello, M ^a   Di Minno, M N D ^a   Romano, A ^a   Gentile, A ^a   Capone, D ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CITALOPRAM; FLUOXETINE; PAROXETINE; SERTRALINE;

ADULT; ARTICLE; BECK DEPRESSION INVENTORY; CHRONIC HEPATITIS; CLINICAL ARTICLE; CONTROLLED STUDY; DEPRESSION; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; HEPATITIS C; HUMAN; MALE; OBESITY; PRIORITY JOURNAL;

ADULT; CASE-CONTROL STUDIES; DEPRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HEPATITIS C, CHRONIC; HUMANS; MALE; MIDDLE AGED; OBESITY; PILOT PROJECTS; SEROTONIN UPTAKE INHIBITORS; SEVERITY OF ILLNESS INDEX;

EID: 49649125867     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/j.1365-2893.2008.01002.x     Document Type: Article

References (27)

1. Haykal RF, Akiskal HS. The long-term outcome of dysthymia in private practice: clinical features, temperament, and the art of management. J Clin Psychiatry 1999 60 : 508 518.
2. Conrad S, Garrett LE, Cooksley WG, Dunne MP, MacDonald GA. Living with chronic hepatitis C means 'you just haven't got a normal life any more'. Chronic Illn 2006 2 : 121 131.
3. el-Serag HB, Kunik M, Richardson P, Rabeneck L. Psychiatric disorders among veterans with hepatitis C infection. Gastroenterology 2002 123 : 476 482.
4. Capuron L, Ravaud A. Prediction of the depressive effects of interferon alfa therapy by the patient's initial affective state. N Engl J Med 1999 340 : 1370.
5. Foster GR, Goldin RD, Thomas HC. Chronic hepatitis C virus infection causes a significant reduction in quality of life in the absence of cirrhosis. Hepatology 1998 27 : 209 212.
6. Bonkovsky HL, Wooley JM. Reduction of health-related quality of life in chronic hepatitis C and improvement with interferon therapy. The Consensus Interferon Study Group. Hepatology 1999 29 : 264 270.
7. Raison CL, Borisov AS, Broadwell SD et al. Depression during pegylated interferon-alpha plus ribavirin therapy: prevalence and prediction. J Clin Psychiatry 2005 66 : 41 48.
8. Wessely S, Pariante C. Fatigue, depression and cronic hepatitis C infection. Psychol Med 2002 32 : 1 10.
9. Van Gool AR, van Ojik HH, Kruit WH et al. Pegylated interferon-alpha2b treatment in melanoma patients: influence and pteridine plasma concentrations. Anticancer Drugs 2004 15 : 587 591.
10. Capuron L, Neurauter G, Musselman DL et al. Interferon-alpha-induced changes in tryptophan metabolism. relationship to depression and paroxetine treatment. Biol Psychiatry 2003 54 : 906 914.
11. Bonaccorso S, Marino V, Puzella A et al. Increased depressive ratings in patients with hepatitis C receiving interferon-alpha-based immunotherapy are related to interferon-alpha-induced changes in the serotonergic system. J Clin Psychopharmacol 2002 22 : 86 90.
12. Pender JR, Pories WJ. Epidemiology of obesity in the United States. Gastroenterol Clin North Am 2005 34 : 1 7.
13. Goldney RD, Phillips PJ, Fisher LJ, Wilson DH. Diabetes, depression, and quality of life: a population study. Diabetes Care 2004 27 : 1066 1070.
14. Kraus MR, Schafer A, Faller H, Csef H, Scheurlen M. Paroxetine for the treatment of interferon-alpha-induced depression in chronic hepatitis C. Aliment Pharmacol Ther 2002 16 : 1091 1099.
15. Richter P, Werner J, Heerlein A, Kraus A, Sauer H. On the validity of the Beck Depression Inventory. A review. Psychopathology 1998 31 : 160 168.
16. Panteleeva GP, Abramova LI, Korenev AN. Selective serotonin reuptake inhibitors in the therapy of various types of endogenous depressions. Zh Nevrol Psikhiatr Im S S Korsakova 2000 100 : 36 41.
17. Wessinger S, Kaplan M, Choi L et al. Increased use of selective serotonin reuptake inhibitors in patients admitted with gastrointestinal haemorrhage: a multicentre retrospective analysis. Aliment Pharmacol Ther 2006 23 : 937 944.
18. Seeff LB, Miller RN, Rabkin CS et al. 45-year follow-up of hepatitis C virus infection in healthy young adults. Ann Intern Med 2000 132 : 105 111.
19. Lerner DM, Stoudomire A, Rosenstein DL. Neurpsychiatric toxicityassociated with cytokine therapies. Psychosomatics 1999 40 : 428 435.
20. Schaefer M, Schwaiger M, Garkisch AS et al. Prevention of interferon-alpha associated depression in psychiatric risk patients with chronic hepatitis C. J Hepatol 2005 42 : 793 798.
21. Kraus MR, Schäfer A, Schöttker K et al. Therapy of interferon-induced depression in chronic hepatitis C with citalopram: a randomized, double-blind, placebo-controlled study. Gut 2008 57 : 531 536.
22. Kraus MR, Schäfer A, Al-Taie O, Scheurlen M. Prophylactic SSRI during interferon alpha re-therapy in patients with chronic hepatitis C and a history of interferon-induced depression. J Viral Hepat 2005 12 : 96 100.
23. Moreira RO, Marca KF, Appolinario JC, Coutinho WF. Increased waist circumference is associated with an increased prevalence of mood disorders and depressive symptoms in obese women. Eat Weight Disord 2007 12 : 35 40.
24. Hauser P, Khosla J, Aurora H et al. A prospective study of the incidence and open-label treatment of interferon-induced major depressive disorder in patients with hepatitis C. Mol Psychiatry 2002 7 : 942 947.
25. Tarantino G, Conca P, Sorrentino P, Ariello M. Metabolic factors involved in the therapeutic response of patients with hepatitis C virus-related chronic hepatitis. J Gastroenterol Hepatol 2006 21 : 1266 1268.
26. Ljung T, Ahlberg AC, Holm G et al. Treatment of abdominally obese men with a serotonin reuptake inhibitor: a pilot study. J Intern Med 2001 250 : 219 224.
27. Zickmund S, Hillis SL, Barnett MJ, Ippolito L, LaBrecque DR. Hepatitis C virus-infected patients report communication problems with physicians. Hepatology 2004 39 : 999 1007.